Medical Devices

InfoBionic Rebrands Company Name to ‘InfoBionic.Ai’, Reinforcing Focus on AI-Enabled ECG

Retrieved on: 
Tuesday, April 9, 2024
Technology, Medical Devices, Health Technology, Telemedicine, Virtual Medicine, Cardiology, Software, Other Health, General Health, Health, Artificial Intelligence, Intelligence, ARC, Machine learning, Mayo Clinic, FDA, Heart, ECG, AI, Medical device

InfoBionic has always been dedicated to remaining at the cutting edge of patient care.

Key Points: 
  • InfoBionic has always been dedicated to remaining at the cutting edge of patient care.
  • Since the organization’s inception in 2015, AI and machine learning have been an integral part of InfoBionic’s remote cardiac telemetry offering.
  • In reality, this name change is just formalizing what we have already become,” says Stuart Long, CEO of InfoBionic.Ai.
  • “Our commitment to evolving remote cardiac telemetry monitoring through existing and novel AI-enabled ECG remains steadfast and unwavering.

Transcat Inc. Announces Executive Leadership Changes

Retrieved on: 
Tuesday, April 9, 2024
Pharmaceutical, Electronic Design Automation, Consumer Electronics, Technology, Medical Devices, Other Manufacturing, Semiconductor, Engineering, Chemicals, Plastics, Biotechnology, Aerospace, Health, Manufacturing, Growth, Inc., CFO, Rudow, TRNS, Accounting, Calibration, Acquisition, Senior, Management

"As we enter the next chapter of Transcat’s growth, I believe it is the right time to transition operations leadership," said Lee Rudow, CEO and President.

Key Points: 
  • "As we enter the next chapter of Transcat’s growth, I believe it is the right time to transition operations leadership," said Lee Rudow, CEO and President.
  • "I look forward to Mike’s leadership as our Chief Operating Officer as we continue to enhance our strong competitive advantages within the markets we serve.
  • Rudow concluded, "On behalf of the entire Company, I'd like to thank Mark for his four years of service to Transcat.
  • During his tenure as CFO and COO, Mark played an important role in repositioning our Company's strategies and building our executive team.

HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias

Retrieved on: 
Tuesday, April 9, 2024
Technology, Medical Devices, Health Technology, Cardiology, Software, Biotechnology, Health, Data Management, Artificial Intelligence, Algorithm, Atrial flutter, Intelligence, Patient, Doctor of Philosophy, MD, Arrhythmia, Vectorcardiography, FDA, VCG, ECG, Medical device

This marks the first scientific presentation on the company’s deep learning algorithm, HeartBeam AI.

Key Points: 
  • This marks the first scientific presentation on the company’s deep learning algorithm, HeartBeam AI.
  • The technology is designed to be used in HeartBeam’s small, portable, patient-friendly devices that allow for remote cardiac monitoring.
  • HeartBeam believes this presents a unique opportunity to create a comprehensive repository of data that could unlock personalized AI-driven insights to improve cardiac care.
  • “As we continue to expand our artificial intelligence capabilities, we look forward to demonstrating how the combination of our data rich 3D VECG platform with HeartBeam AI has the potential to transform how cardiac health is managed in the future.”

S2 Genomics Announces Groundbreaking Single Cell FFPE Sample Prep Isolation Product

Retrieved on: 
Tuesday, April 9, 2024
Chemicals, Plastics, Electronic Design Automation, Manufacturing, Technology, Stem Cells, Pharmaceutical, Oncology, Medical Devices, Genetics, Clinical Trials, Other Manufacturing, Other Technology, Biotechnology, Science, Research, Health, Genomics, Tissue, RNA, The central science, Antibiotics

S2 Genomics, a pioneer in tissue sample preparation systems, today announced the launch of its latest product, the Singulator™ 200+ System, an automated sample prep isolation system for single cell formalin-fixed, paraffin-embedded (FFPE) tissues.

Key Points: 
  • S2 Genomics, a pioneer in tissue sample preparation systems, today announced the launch of its latest product, the Singulator™ 200+ System, an automated sample prep isolation system for single cell formalin-fixed, paraffin-embedded (FFPE) tissues.
  • The new FFPE sample prep isolation system is designed to isolate nuclei from FFPE tissue slices, enabling single-nucleus RNA sequencing (snRNA-Seq) for FFPE samples.
  • Jonathan Schimmel, President and CEO of S2 Genomics, expressed his enthusiasm for the new product: “The FFPE sample prep isolation system is a testament to our commitment to continuing innovation and excellence in the field of single cell genomics.
  • For more information about the FFPE sample prep isolation system and other S2 Genomics products, please visit us at s2genomics.com or connect with us on LinkedIn or Twitter .

Emet Surgical Accepted into Innosphere Ventures Life Sciences Incubator Program

Retrieved on: 
Tuesday, April 9, 2024
Oncology, Medical Devices, Health, Surgery, Other Health, General Health, U.S. FDA, ROI, Entrepreneurship, Cancer, Surgeon, Ecosystem, Pathology, Orientation

Emet Surgical , developers of innovative tools to improve surgery outcomes, today announced its acceptance into the Innosphere Ventures Life Sciences Incubator for pioneering startups, a program of impact nonprofit Innosphere Ventures .

Key Points: 
  • Emet Surgical , developers of innovative tools to improve surgery outcomes, today announced its acceptance into the Innosphere Ventures Life Sciences Incubator for pioneering startups, a program of impact nonprofit Innosphere Ventures .
  • Innosphere’s incubation programs support the commercialization efforts of entrepreneurs, technical founders and university researchers who are launching and scaling high-tech startups.
  • The Innosphere Ventures Regional Life Sciences Incubator accelerates the success of founders building technology and science-based companies through its incubation programs, office and specialized wet laboratory facilities, and venture capital funds.
  • "Emet Surgical’s innovative approach to improving surgery outcomes, born out of firsthand experience and a commitment to addressing critical challenges in the field, exemplifies the spirit of entrepreneurship and innovation that defines our cohort,” said Kevin Noble, Life Sciences Program Director for Innosphere.

New Study Finds AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration and Significantly Reduce False Alarms for Clinicians

Retrieved on: 
Tuesday, April 9, 2024
Software, Telemedicine, Virtual Medicine, Health, FDA, Artificial Intelligence, Medical Devices, Health Technology, Technology, Hospital, UMass Memorial Health, Data science, Caregiver, Risk, CLEW, Journal, Mortality, Intensive care unit, Telehealth, MD, Respiratory failure, Critical care, WakeMed, Nursing care plan, Fatigue, ICU

The prediction models used in the study are a part of CLEW’s intelligent clinical surveillance platform.

Key Points: 
  • The prediction models used in the study are a part of CLEW’s intelligent clinical surveillance platform.
  • It also supports the health system with capacity management, by providing early identification of potential bottlenecks caused by unexpected deterioration.
  • In addition to demonstrating its superior accuracy, the study concluded that the CLEW system generated 50-times fewer alarms than other leading systems.
  • In busy and overburdened critical care environments, this can greatly reduce alarm fatigue and the associated cognitive burden on caregivers.

Q Bio Unveils New MRI Technology - Tensor Field Mapping - Advancing Measurement in Medical Imaging

Retrieved on: 
Tuesday, April 9, 2024
Medical Devices, Health, Technology, Health Technology, Artificial Intelligence, Diagnosis, Physics, Benchmarking, GPU, MRI, Magnetic resonance imaging, Patient, Tissue, Research, AI, Software, TFM, Magnetic resonance, Medical imaging

Q Bio Inc. , an innovator in medical imaging technology, today announced the launch of Tensor Field Mapping (TFM) , a new technology for Magnetic Resonance Imaging (MRI) that provides detailed insights into the human body that were previously unimaginable.

Key Points: 
  • Q Bio Inc. , an innovator in medical imaging technology, today announced the launch of Tensor Field Mapping (TFM) , a new technology for Magnetic Resonance Imaging (MRI) that provides detailed insights into the human body that were previously unimaginable.
  • "Tensor Field Mapping is more than an innovative technology; it's a vision for the future of medical imaging where frequency, accuracy, and benchmarking with commodity radiomic data is possible," added Clarissa Shen, COO, Q Bio.
  • Q Bio Inc. is committed to advancing medical imaging technology and improving patient outcomes.
  • With the launch of Tensor Field Mapping, the company is at the forefront of a new era in diagnostics and personalized medicine.

Real Time Medical Systems Brings Post-acute Care Focus to NAACOS Spring 2024 Conference

Retrieved on: 
Tuesday, April 9, 2024
Software, Managed Care, General Health, Professional Services, Medical Devices, Technology, Infectious Diseases, Hospitals, Data Analytics, Clinical Trials, Nursing, Health, RN, ACO, Conference, Acos, KLAS, HITRUST, Real, Real-time, Patient, Policy, Senior, Circle, Length of stay, EHR, National Association, CMS

Real Time Medical Systems (Real Time), the industry leading, KLAS Rated, and HITRUST Certified post-acute analytics solution, announced today its presence at the National Association of ACOs (NAACOS) Spring 2024 Conference on April 10-12, 2024.

Key Points: 
  • Real Time Medical Systems (Real Time), the industry leading, KLAS Rated, and HITRUST Certified post-acute analytics solution, announced today its presence at the National Association of ACOs (NAACOS) Spring 2024 Conference on April 10-12, 2024.
  • Real Time joins CMS officials, ACO leaders, and policy insiders in Baltimore, MD, to demonstrate how providers can reduce hospital admissions/readmissions, minimize length of stay, and improve care coordination in the post-acute setting through Real Time’s interventional analytics platform.
  • The session takes place on Thursday, April 11, 2024, at 7:30am – 8:15am.
  • “I thoroughly enjoy speaking to the NAACOS audience,” states Phyllis Wojtusik, RN.

SimBioSys Launches TumorSight Plan, A Pioneering Clinical Decision Support for Early-Stage Breast Cancer

Retrieved on: 
Tuesday, April 9, 2024
Technology, Biotechnology, Health, Consumer, Other Health, Radiology, Surgery, Artificial Intelligence, Oncology, Medical Devices, Software, General Health, Health Technology, Women, Breast cancer, MRI, Breast Cancer Care, Mastectomy, Science, Patient, Artificial intelligence, 3D, Cancer, Surgeon, Woman, Risk assessment, CMO, Simbiosys, FDA, Medicine, Medical imaging

Now, with TumorSight Plan, surgeons are empowered with visualization, data-driven insights, and best-practices to help support more effective provider-patient interactions and individualize treatment planning to right-size care.

Key Points: 
  • Now, with TumorSight Plan, surgeons are empowered with visualization, data-driven insights, and best-practices to help support more effective provider-patient interactions and individualize treatment planning to right-size care.
  • TumorSight Plan is powered by the FDA-cleared TumorSight Viz , an innovative 3D visualization solution to support the rapidly increasing use of MRI imaging in Breast Cancer.
  • SimBioSys’ TumorSight suite is a huge breakthrough in our capacity to utilize AI to calibrate a balance between decision standardization and individualized medicine.
  • TumorSight Plan gives the breast cancer surgeon a platform and opportunity to enable more analytical patient-centric decision making which should lead to higher percentage of women undergoing breast conservation surgery.”

CG Life Acquires Toolhouse, Significantly Expanding Technology-Enabled Omnichannel Capabilities

Retrieved on: 
Tuesday, April 9, 2024
Search Engine Marketing, Data Management, Other Communications, Technology, Public Relations, Investor Relations, Marketing, Advertising, Pharmaceutical, Communications, General Health, Medical Devices, Other Technology, Biotechnology, Software, Digital Marketing, Health, Organization, Science, Digital, Patient, Acquisition, Senior, Creativity, Multimedia, Physician, Sales

CG Life , a leading integrated agency that blends strategy, creative, marketing, digital, and media with science, has significantly expanded its ability to support commercial life science organizations with digital omnichannel strategies through the addition of Toolhouse .

Key Points: 
  • CG Life , a leading integrated agency that blends strategy, creative, marketing, digital, and media with science, has significantly expanded its ability to support commercial life science organizations with digital omnichannel strategies through the addition of Toolhouse .
  • View the full release here: https://www.businesswire.com/news/home/20240409702768/en/
    CG Life acquires Toolhouse to expand its technology-enabled omnichannel capabilities for biopharma and life science companies (Photo: Business Wire)
    Founded in 1995, Toolhouse is a digital agency specializing in helping biopharma companies create more meaningful, measurable connections with patients and physicians.
  • “Healthcare has changed dramatically, requiring brand leaders in biopharma and life science to deploy nimble, omnichannel digital strategies to connect with their audiences,” said CG Life CEO David Ormesher.
  • “The decision for Toolhouse to join forces with the CG Life team was a completely natural one.